CARDIOLITE

This brand name is authorized in Hong Kong, Israel, Japan, United States, South Africa

Active ingredients

The drug CARDIOLITE contains one active pharmaceutical ingredient (API):

1 Technetium ⁹⁹ᵐTc sestamibi UNII N6OU7HJ70P - TETRAKIS(2-METHOXYISOBUTYLISOCYANIDE)COPPER(I) TETRAFLUOROBORATE

Technetium 99mTc sestamibi is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands, hence the name sesta (6) MIBI. Following intravenous injection of the drug, Technetium 99mTc sestamibi is taken up by the myocardium, parathyroid, and/or breast tissue. Read about Technetium ⁹⁹ᵐTc sestamibi

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CARDIOLITE Powder for solution, lyophilized	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V09GA01	Technetium (99mTc) sestamibi	V Various → V09 Diagnostic radiopharmaceuticals → V09G Cardiovascular system → V09GA Technetium (99mTc) compounds
Discover more medicines within V09GA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: HK	Department of Health Drug Office	Identifier(s): 43085
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 6580
Country: JP	医薬品医療機器総合機構	Identifier(s): 4300439D1024, 4300440D1027, 4300440D2023, 4300440D3020, 4300440D4026
Country: US	FDA, National Drug Code	Identifier(s): 11994-001
Country: ZA	Health Products Regulatory Authority	Identifier(s): Z/35/108